Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 525Ovarian function and disordersClinical practice guidelines implementationEndometriosis Research and Treatment

The DOI matches its Crossref record; 13 of the 14 references it cites were found in a registry or an index; 7 of the 18 sources its claims cite were checked for support.

Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome

Open access
Teede, Helena J, Tay, Chau Thien, Laven, Joop J E, Dokras, Anuja, Moran, Lisa J, Piltonen, Terhi T, Costello, Michael F, Boivin, Jacky, Redman, Leanne M, Boyle, Jacqueline A, Norman, Robert J, Mousa, Aya, Joham, Anju E, the International PCOS Network, Arlt, Wiebke, Azziz, Ricardo, Balen, Adam, Bedson, Lisa, Berry, Lorna, Boivin, Jacky, Boyle, Jacqueline, Brennan, Leah, Brown, Wendy, Burgert, Tania, Busby, Maureen, Ee, Carolyn, Garad, Rhonda M, Gibson-Helm, Melanie, Harrison, Cheryce, Hart, Roger, Hopkins, Kim, Hirschberg, Angelica Lindén, Ho, Tuong, Hoeger, Kathleen, Jordan, Cailin, Legro, Richard S, Li, Rong, Lujan, Marla, Ma, Ronald, Mansfield, Darren, Marsh, Kate, Mocanu, Edgar, Mol, Ben, Mormon, Rachel, Norman, Robert, Oberfield, Sharon, Patel, Malika, Pattuwage, Loyal, Peña, Alexia, Redman, Leanne, Rombauts, Luk, Romualdi, Daniela, Shah, Duru, Spritzer, Poli Mara, Stener-Victorin, Elisabet, Tehrani, Fahimeh Ramezani, Thangaratinam, Shakila, Thondan, Mala, Vanky, Eszter, Wijeyaratne, Chandrika, Witchel, Selma, Yang, Dongzi, Yildiz, Bulent, Alesi, Simon, Alur-Gupta, Snigdha, Avery, Jodie, Khomami, Mahnaz Bahri, Benham, Jamie, Bidstrup, Hugh, Chua, Su Jen, Cooney, Laura, Coster, Thisara, Ee, Carolyn, Fitz, Victoria, Flanagan, Madeline, Forslund, Maria, Jiskoot, Geranne, Kazemi, Maryam, Kempegowda, Punith, Louwers, Yvonne, Lujan, Marla, Melin, Johanna, Melson, Eka, Mengistu, Yitayeh Belsti, Naderpoor, Negar, Neven, Adriana, Pastoor, Hester, Rocha, Thais, Sabag, Angelo, Subramanian, Anuradhaa, Tan, Katrina·2023·European Journal of Endocrinology

Abstract

Study question: What is the recommended assessment and management of those with polycystic ovary syndrome (PCOS), based on the best available evidence, clinical expertise, and consumer preference? Summary answer: International evidence-based guidelines address prioritized questions and outcomes and include 254 recommendations and practice points, to promote consistent, evidence-based care and improve the experience and health outcomes in PCOS. What is known already: The 2018 International PCOS Guideline was independently evaluated as high quality and integrated multidisciplinary and consumer perspectives from 6 continents; it is now used in 196 countries and is widely cited. It was based on best available, but generally very low- to low-quality, evidence. It applied robust methodological processes and addressed shared priorities. The guideline transitioned from consensus-based to evidence-based diagnostic criteria and enhanced accuracy of diagnosis, whilst promoting consistency of care. However, diagnosis is still delayed, the needs of those with PCOS are not being adequately met, the evidence quality was low, and evidence-practice gaps persist. Study design, size, and duration: The 2023 International Evidence-based Guideline update re-engaged the 2018 network across professional societies and consumer organizations with multidisciplinary experts and women with PCOS directly involved at all stages. Extensive evidence synthesis was completed. Appraisal of Guidelines for Research and Evaluation II (AGREEII)-compliant processes were followed. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework was applied across evidence quality, feasibility, acceptability, cost, implementation, and ultimately recommendation strength, and diversity and inclusion were considered throughout. Participants/materials, setting, and methods: This summary should be read in conjunction with the full guideline for detailed participants and methods. Governance included a 6-continent international advisory and management committee, 5 guideline development groups, and paediatric, consumer, and translation committees. Extensive consumer engagement and guideline experts informed the update scope and priorities. Engaged international society-nominated panels included paediatrics, endocrinology, gynaecology, primary care, reproductive endocrinology, obstetrics, psychiatry, psychology, dietetics, exercise physiology, obesity care, public health, and other experts, alongside consumers, project management, evidence synthesis, statisticians, and translation experts. Thirty-nine professional and consumer organizations covering 71 countries engaged in the process. Twenty meetings and 5 face-to-face forums over 12 months addressed 58 prioritized clinical questions involving 52 systematic and 3 narrative reviews. Evidence-based recommendations were developed and approved via consensus across 5 guideline panels, modified based on international feedback and peer review, independently reviewed for methodological rigour, and approved by the Australian Government National Health and Medical Research Council. Main results and the role of chance: The evidence in the assessment and management of PCOS has generally improved in the past 5 years but remains of low to moderate quality. The technical evidence report and analyses (∼6000 pages) underpin 77 evidence-based and 54 consensus recommendations, with 123 practice points. Key updates include the following: (1) further refinement of individual diagnostic criteria, a simplified diagnostic algorithm, and inclusion of anti-Müllerian hormone levels as an alternative to ultrasound in adults only; (2) strengthening recognition of broader features of PCOS including metabolic risk factors, cardiovascular disease, sleep apnoea, very high prevalence of psychological features, and high risk status for adverse outcomes during pregnancy; (3) emphasizing the poorly recognized, diverse burden of disease and the need for greater healthcare professional education, evidence-based patient information, improved models of care, and shared decision-making to improve patient experience, alongside greater research; (4) maintained emphasis on healthy lifestyle, emotional well-being, and quality of life, with awareness and consideration of weight stigma; and (5) emphasizing evidence-based medical therapy and cheaper and safer fertility management. Limitations and reasons for caution: Overall, recommendations are strengthened and evidence is improved but remains generally low to moderate quality. Significantly greater research is now needed in this neglected, yet common condition. Regional health system variation was considered and acknowledged, with a further process for guideline and translation resource adaptation provided. Wider implications of the findings: The 2023 International Guideline for the Assessment and Management of PCOS provides clinicians and patients with clear advice on best practice, based on the best available evidence, expert multidisciplinary input, and consumer preferences. Research recommendations have been generated, and a comprehensive multifaceted dissemination and translation programme supports the guideline with an integrated evaluation programme.

Overview

CoChat Summary

TL;DR

The 2023 international evidence-based guideline update provides 254 recommendations and practice points for PCOS assessment and management, including 77 evidence-based and 54 consensus recommendations plus 123 practice points. It emphasizes refined diagnosis (including AMH as an alternative to ultrasound in adults only), broader metabolic/cardiovascular/psychological risk recognition, lifestyle and shared decision-making, and evidence-based fertility management, while noting evidence remains low to moderate quality.

Key findings

  • The guideline includes 254 recommendations and practice points; a technical report of ∼6000 pages underpins 77 evidence-based and 54 consensus recommendations, with 123 practice points.
  • Diagnostic updates: PCOS should be diagnosed using the 2018 criteria requiring 2 of clinical/biochemical hyperandrogenism, ovulatory dysfunction, and polycystic ovaries; AMH can now be used instead of ultrasound in adults only, but not in adolescents; when irregular cycles and hyperandrogenism are present, ultrasound or AMH are not required for diagnosis.
  • PCOS prevalence is 10%–13% globally and is associated with increased risks including cardiovascular disease, impaired glucose tolerance/type 2 diabetes, obstructive sleep apnoea independent of BMI, endometrial hyperplasia/cancer, high prevalence of moderate to severe depressive/anxiety symptoms, and higher-risk pregnancy.
  • Management recommendations include healthy lifestyle for all, no single diet or exercise type shown superior, COCP as first-line pharmacological treatment for menstrual irregularity/hyperandrogenism, metformin primarily for metabolic features, letrozole as first-line ovulation induction, gonadotrophins or laparoscopic ovarian surgery as second-line, and IVF as third-line where first- or second-line therapies fail.

Methods

  • The 2023 update re-engaged the 2018 network across 39 professional and consumer organizations covering 71 countries, with 5 guideline development groups (56 members), 20 meetings and 5 face-to-face forums over 12 months, and 52 systematic plus 3 narrative reviews. The abstract reports 58 prioritized clinical questions; the Materials and methods section reports 55.
  • AGREEII-compliant processes were followed, and the GRADE framework was applied across evidence quality, feasibility, acceptability, cost, implementation, and recommendation strength, with diversity and inclusion considered throughout.
  • Evidence synthesis and meta-analysis were completed; recommendations were developed and approved via consensus across 5 guideline panels, modified after international feedback and peer review, independently reviewed for methodological rigour, and approved by the Australian Government National Health and Medical Research Council.

Limitations

  • The paper states that recommendations are strengthened and evidence has improved but remains generally low to moderate quality, and that significantly greater research is needed in this neglected yet common condition.
  • The paper states that regional health system variation was considered and acknowledged, with a further process for guideline and translation resource adaptation provided; it also notes that certainty of evidence varied across outcomes and reflects the lowest certainty for critical outcomes.
  • The text makes evident that this article is a summary and refers readers to the full guideline and technical report for detailed participants and methods; it also contains a minor internal inconsistency in the reported number of prioritized clinical questions (58 vs 55).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/ejendo/lvad096

Cites

13 of 14 references verified0 citation errors · 1 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

6 Valid · 66 Not valid · 4 Not checked · 80 Own results and interpretations

37 more claims

Create a free account to see all 156 claims and to verify the 1 reference still open.

See all claims — free account
  • Probably not a substantial claim. 109
  • It may state two separate claims as one. 32

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 11 references

Cited by

See all 525

Metadata

Authors
Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., Joham, A. E., the International PCOS Network, Arlt, W., Azziz, R., Balen, A., Bedson, L., Berry, L., Boivin, J., Boyle, J., Brennan, L., Brown, W., Burgert, T., Busby, M., Ee, C., Garad, R. M., Gibson-Helm, M., Harrison, C., Hart, R., Hopkins, K., Hirschberg, A. L., Ho, T., Hoeger, K., Jordan, C., Legro, R. S., Li, R., Lujan, M., Ma, R., Mansfield, D., Marsh, K., Mocanu, E., Mol, B., Mormon, R., Norman, R., Oberfield, S., Patel, M., Pattuwage, L., Peña, A., Redman, L., Rombauts, L., Romualdi, D., Shah, D., Spritzer, P. M., Stener-Victorin, E., Tehrani, F. R., Thangaratinam, S., Thondan, M., Vanky, E., Wijeyaratne, C., Witchel, S., Yang, D., Yildiz, B., Alesi, S., Alur-Gupta, S., Avery, J., Khomami, M. B., Benham, J., Bidstrup, H., Chua, S. J., Cooney, L., Coster, T., Ee, C., Fitz, V., Flanagan, M., Forslund, M., Jiskoot, G., Kazemi, M., Kempegowda, P., Louwers, Y., Lujan, M., Melin, J., Melson, E., Mengistu, Y. B., Naderpoor, N., Neven, A., Pastoor, H., Rocha, T., Sabag, A., Subramanian, A., & Tan, K.
Affiliations
  • Monash Health (AU)
  • National Health and Medical Research Council Centre for Research Excellence in Women's Health in Reproductive Life , Australia
  • University of Pennsylvania (US)
  • Oulu University Hospital (FI)
  • UNSW Sydney (AU)
  • Pennington Biomedical Research Center , Louisiana State University, Baton Rouge, LA , United States
  • Cardiff University (GB)
  • Eastern Health (AU)
  • National Health and Medical Research Council (AU)
  • Pennington Biomedical Research Center (US)
Corresponding author
Teede, Helena J
Venue
European Journal of Endocrinology
Published
2023-08
Volume
189
Issue
2
Pages
G43-G64
ISSN
  • 0804-4643 (ISSN-L)
  • 1479-683X
OpenAlex
W4385827828
Cited by
525
References
11
Citations by year
2026: 229 · 2025: 177 · 2024: 102 · 2023: 16
FWCI
125.57
Type
journal article
Language
en
Open access
Locations
  • European Journal of Endocrinology (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by-nc)
  • ePrints Soton (University of Southampton) (submittedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by-nc)
Funders
  • National Health Medical Research Council (APP1171592)
  • American Society for Reproductive Medicine
  • Endocrine Society
  • European Society for Human Reproduction and Embryology
  • Society for Endocrinology
  • Commonwealth Government of Australia
  • Medical Research Future Fund (MRFCRI000266)
  • NHMRC
  • Royal Australasian College of Physicians
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
  • Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
Keywords
polycystic ovary syndrome, PCOS diagnosis, PCOS management, diagnostic criteria, infertility, hyperandrogenism, insulin resistance, obesity, customer engagement, shared decision-making, knowledge-practice gap, guideline recommendations, AGREE II, GRADE, multidisciplinary care, health outcomes, quality of life
MeSH terms
Adult, Australia, Female, Humans, Polycystic Ovary Syndrome, Pregnancy, Quality of Life, Risk Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. https://app.cochat.ai/papers/10.1093/ejendo/lvad096
The paper
Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., Joham, A. E., the International PCOS Network, Arlt, W., Azziz, R., Balen, A., Bedson, L., Berry, L., . . . Tan, K. (2023). Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvad096

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.